Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christian Mayr

Showing results (1-10 of 72) with videos related to

Pageof 8
Sort By:
Expert Opinion on Investigational Drugs|April 20, 2021
The challenges of combinatory immunotherapy for biliary tract cancerDaniel Neureiter, Christian Mayr, Tobias Kiesslich
Computational Intelligence and Neuroscience|July 9, 2009
On the relation between bursts and dynamic synapse properties: a modulation-based ansatzChristian Mayr, Johannes Partzsch, Rene Schüffny
Ebiomedicine|October 26, 2019
NRF2: The key to tumor- and patient-dependent chemosensitivity in biliary tract cancer?Tobias Kiesslich, Christian Mayr, Daniel Neureiter
Expert Opinion on Pharmacotherapy|January 5, 2020
How do we choose the appropriate chemotherapeutic agents for biliary tract cancer?Daniel Neureiter, Christian Mayr, Tobias Kiesslich
Translational Oncology|April 19, 2024
New insights into possible HDAC inhibitor resistance in DLBCL - Comment on 'defining cellular responses to HDAC-selective inhibitors reveals that efficient targeting of HDAC3 is required to elicit cytotoxicity and overcome naïve resistance to pan-HDACi in diffuse large B cell lymphoma' by Havas et alTobias Kiesslich, Christian Mayr, Dino Bekric, et al.
Breast Care (Basel, Switzerland)|June 16, 2011
Breast Sonography - 2D, 3D, 4D Ultrasound or Elastography?Christian Weismann, Christian Mayr, Heike Egger, et al.
Expert Opinion on Therapeutic Targets|November 18, 2017
Update on the role and therapeutic potential of polycomb repressive complexes in (biliary tract) cancerDaniel Neureiter, Tobias Kiesslich, Markus Ritter, et al.
Cancers|April 3, 2021
Immunmodulatory Treatment Strategies of Hepatocellular Carcinoma: From Checkpoint Inhibitors Now to an Integrated Approach in the FutureMatthias Ocker, Christian Mayr, Tobias Kiesslich, et al.
Expert Opinion on Therapeutic Targets|November 27, 2014
The role of polycomb repressive complexes in biliary tract cancerChristian Mayr, Daniel Neureiter, Andrej Wagner, et al.
Expert Opinion on Emerging Drugs|June 3, 2026
Emerging claudin-18.2 antagonists in the treatment of biliary tract cancerDaniel Neureiter, Dino Bekric, Christian Mayr, et al.
Pageof 8

Showing results (1-10 of 72) with videos related to

Sort By:
Pageof 8
Expert Opinion on Investigational Drugs|April 20, 2021
The challenges of combinatory immunotherapy for biliary tract cancerDaniel Neureiter, Christian Mayr, Tobias Kiesslich
Computational Intelligence and Neuroscience|July 9, 2009
On the relation between bursts and dynamic synapse properties: a modulation-based ansatzChristian Mayr, Johannes Partzsch, Rene Schüffny
Ebiomedicine|October 26, 2019
NRF2: The key to tumor- and patient-dependent chemosensitivity in biliary tract cancer?Tobias Kiesslich, Christian Mayr, Daniel Neureiter
Expert Opinion on Pharmacotherapy|January 5, 2020
How do we choose the appropriate chemotherapeutic agents for biliary tract cancer?Daniel Neureiter, Christian Mayr, Tobias Kiesslich
Translational Oncology|April 19, 2024
New insights into possible HDAC inhibitor resistance in DLBCL - Comment on 'defining cellular responses to HDAC-selective inhibitors reveals that efficient targeting of HDAC3 is required to elicit cytotoxicity and overcome naïve resistance to pan-HDACi in diffuse large B cell lymphoma' by Havas et alTobias Kiesslich, Christian Mayr, Dino Bekric, et al.
Breast Care (Basel, Switzerland)|June 16, 2011
Breast Sonography - 2D, 3D, 4D Ultrasound or Elastography?Christian Weismann, Christian Mayr, Heike Egger, et al.
Expert Opinion on Therapeutic Targets|November 18, 2017
Update on the role and therapeutic potential of polycomb repressive complexes in (biliary tract) cancerDaniel Neureiter, Tobias Kiesslich, Markus Ritter, et al.
Cancers|April 3, 2021
Immunmodulatory Treatment Strategies of Hepatocellular Carcinoma: From Checkpoint Inhibitors Now to an Integrated Approach in the FutureMatthias Ocker, Christian Mayr, Tobias Kiesslich, et al.
Expert Opinion on Therapeutic Targets|November 27, 2014
The role of polycomb repressive complexes in biliary tract cancerChristian Mayr, Daniel Neureiter, Andrej Wagner, et al.
Expert Opinion on Emerging Drugs|June 3, 2026
Emerging claudin-18.2 antagonists in the treatment of biliary tract cancerDaniel Neureiter, Dino Bekric, Christian Mayr, et al.
Pageof 8